We include in this article the results of a postal inquiry into chronic pain in SCI patients in Valencia (Spain), and our experience with their management. A mailed questionaire including lesion and chronic pain data was sent to al\ of the 380 SCI patients who live in the region of Valencia. We received 202 answers, with 145 questionaires being accurately answered and these were analysed for this study. The results show that chronic pain (that is, lasting more than 6 months) is very common (65.5. %).
Introduction
Chronic pain after spinal cord injury (SCI) has been reported to occur in 40-100% of patients.1-3 The aetiology and clinical pre sentation has focused on different aspects and many classifications have been pro posed. 4 -7 Because of the difficulty of successful management, a wide variety of treatments have been used with variable results. 8 In this study we have summarised the results from a questionnaire on pain accur ately answered by 145 SCI patients. We also report on our pharmacological approach to the treatment of these patients.
Material and methods
A mailed questionnaire requesting data about SCI and pain was sent to all 380 members of the national association of SCI patients living in the region of Valencia. We received 202 answers (53% ): 57 question naires with defects, failures or controversy in the answers were rejected. The remaining 145 questionnaires were accurately com pleted and were included in this study.
Different qualities of pain were sug gested in the questionnaire (burning, sharp, aching, throbbing, shooting, etc), along with a request to provide a diagram and shade in the painful areas, questions about the body positions that made the pain worse, and both the Lattinen and visual analogue scale test with instructions for accurate answers.
Our therapeutic experience is based on the management of the 33 patients with chronic pain who have been sent to the pain unit by the rehabilitation department in the last 4 years. The sample is described in Table I .
In 1987 we proposed a management approach based on three steps. For those patients who failed to obtain satisfactory analgesia, we added a new therapeutic step: the continuous intrathecal perfusion of morphine (Table II) .9. 1 0 Although there is no general agreement on the criteria for choosing intrathecal opioids, we chose this way based on the previous literature and on our own experi ence in cancer pain . 1l-I4 In addition, the new internal pumps programmed by tele metry simplify the use of the intrathecal route. Finally. the use of intrathecal mor phine seems to benefit spasti_ city, as has been reported in other studies.
i).In
The treatment was given according to our 'step programme'. When the therapy was not successful the patients passed to the next Regarding the first step, low initial doses of amitryptiline (30 mg/day) were given, and were increased to 75 mg/day after an adaptation period of 10 days. Clonazepam was administered in drops for a more convenient dosing, using low doses (0.6-1.5 mg/day). As an analgesic, we added an antiinflammatory drug, especially for painful musculoskeletal conditions. Patients were always informed about all possible side effects, and were given our telephone number.
Some patients were taking baclofen orally to treat spasticity: this drug was not with drawn. However, all analgesic drugs were suppressed before starting our therapeutic protocol. Patients with psychiatric disorders were excluded. If good pain control was not achieved and patients asked for more anal gesia, we began the second step after a peroid of 35 days. This was focused on neuromodulation, changing the antiinflam matory drug for 5-0H-Tryptophane (300 mg/day), and adding TENS.
The model of TENS used was a 'Pulsar' (Spembly Medical) which has two channels and four electrodes. We always started with conventional stimulation (rate: 90 Hz, PW:
75 {LS, and low amplitude: 10-30 rnA) to produce a comfortable tingling sensation. Two electrodes were placed at the lower paravertebral dermatome with sensibility, and another two over the painful derma tomes.
If satisfactory pain relief was not ob tained, the patients were advised to change the device controls in order to try to obtain a better response. A period of stimulation for between 3 and 6 hours daily was recom mended according to individual require ments.
If improvement was not obtained after a trial period of 30-40 days and psychological problems were ruled out, the spinal cord stimulation technique was explained to the patient, and was then implanted after a waiting period of 2-3 months if this treat ment was accepted by the patient.
Under local anaesthesia, a tetrapolar electrode was introduced into the posterior epidural space through a Tuohy needle placing it in the central and posterior level of T9-10 to stimulate the lower limbs.
The electrode was connected to a test stimulator and, under fluoroscopy, was manipulated to elicit paraesthesiae in the affected painful area. Using percutaneous extension wires, 1 week of stimulation trial was performed.
If sufficient relief was achieved after the trial of a week, the electrode system was permanently implanted, connecting it sub cutaneously to a generator (ltrel II) in an abdominal pocket under local anaesthesia. The current parameters were modulated until comfortable paraesthesiae were felt.
The results of the study have been as sessed using the Lattinen test, the visual analogue scale and the subjective opinions of family members about changes in the patients' quality of life. The Lattinen test is used as a rule in the first evaluation of all patients in our pain unit. It consists of five groups of easy questions on pain, with four possible answers in each one. Every group is scored from 0 to 4 points. The total score is obtained by adding the score of each selected word in the five groups of questions (maximum 20 points). The test provides information about the intensity of pain, frequency, analgesics intake, disability, and sleep (Table III) .1 7
The patients who were chosen for the intrathecal infusion were previously sub mitted to a three doses test of intrathecal morphine (one dose every 48 hours) in order to evaluate any possible side effects and the degree of analgesia achieved. We always started with 0.6 mg and continued ParapiCRia 31 (1993) 722-729 
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Choose one \\ord in each group: score 0-20.
with 0.3-1 mg according to the response obtained. We consider it to be of great importance to inform the patient of all possible side effects of intrathecal mor phine.
After assessing the results of the three doses test, the implant of an internal infu sion pump ('SynchroMed B611 H'. Med tronic Inc) was considered in patients who achieved a degree of analgesia of over 50% and lasting at least 12 hours. A continuous infusion using 0.6 mg/day was started in the implanted patients.
All patients had an initial evaluation of pain severity, with assessment and follow up evaluation at 3, 6, 12. 18, 24 and 36 months after implanting the pump.
Results
The data obtained from the postal survey are summarised in the tables (Tables IV, V Paraplegia 31 � \993) 722-729 
13-70
Mean age at time of lesion 25.5 and VII) . We can summarISC our results statistically:
1 Chronic pain in SCI is very frequent (65.5% ) . 2 Most of the patients (52% ) described the pain as being continuous, burning or as a painful numbness, with a pain less period of time following the lesion, so that we may consider deafferenta tion pain as being the most common type. Other types of pain described were: 'like electricity' (9% ), pressure (7% ) and poorly defined (32% ). 
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"Average intensity = 12 points (Lattin en scale).
3 There were no differences related to sex, type of lesion or aetiology of the SCI. 4 Pain was more frequent in patients with cervical and lumbar lesions; those aged over 50 years; and patients with spast icity.
The current distribution of patients ac cording to our management approach is shown in Table VII. Satisfactory pain relief was noted in six The results concerning analgesia have been excellent, with pain relief in 80% on average in all cases; however, some paraes thetic sensation persisted.
We have to point out that the patients who achieved a better response to SCS were those with incomplete lesions and radicular pain. We could not obtain any benefit in patients with complete lesions and deaf ferentation pain, as has been reported in previous studies. 1 R The doses of intrathecal morphine used in each patient and the degree of tolerance developed after 3 years, are shown in Table   VIII .
In our study we also found improvement in spasticity after using intrathecal mor phine, according to the results obtained by Erickson and Milller, 1 5,16 but it was not scored.
Regarding complications, in two patients it was necessary to replace the intrathecal catheter due to displacement. The patients noted the misplacement because of re appearance of their pain.
Discussion
Even though a questionnaire letter does not appear to be the best way to obtain medical information, the answers in our protocol Paraplegia 31 (1993) 722-729 were very easy to understand. All patients were advised to review their medical reports to complete the questionnaire. The medical histories were occasionally reviewed. We included the words that our patients use to define the pain in our pain unit. All incom plete questionnaires and those with con fused answers were rejected.
Regarding the use of invasive techniques the following questions can be considered.
Pain management
SCS has been used for pain management since 1967 with differing results.1Y Melio et a("() reported a survey of 109 patients treated with SCS. The best results were obtained in those with vascular pain, whereas central pain was only improved in 30% of cases. Cole et al17 have recently reported that SCS may be used with good results in patients suffering from central pain only when ascending pathways remain undamaged. Therefore. this technique does not seem to be reliable for patients with complete SCI, as we have observed in our patients.
Why use morphine?
Although there is no general agreement on the criteria for choosing morphine for de afferentation pain,n-c3 many authors have reported very good results in the treatment of this type of pain in patient with posther petie neuralgia, multiple sclerosis, reflex sympathetic dystrophy, or SCI y -c6 More over, we know that the use of intrathecal morphine is very safe in spite of a prolonged infusion. These results were challenging enough to try the use of intrathecal mor phine in patients suffering unbearable pain 
Tolerance and dependence
The epidural route has been proved to generate more tolerance than the intra t?ecal one . because of its systemic absorp tIOn, thus It should not be used in patients with a long life expectancyY A repetitive bolus of morphine may generate many complications when used over a long period of time (more risk of infections, drug dependence problems if it is used at home, more tolerance, etc) thus the continuous infusion is an important alternative for the management of nonmalignant pain.
The development of tolerance seems to be the most important problem in long term treatment, and some authors refuse to use morphine in patients with chronic, non cancer pain.
21.2R.29
None of our eight patients developed a significant degree of tolerance after 3 years of treatment using continuous intrathecal perfusion. No withdrawal syndromes were observed. We did not find physical or psychological dependence. These findings were consistent with previous studies. 30 As we have recently demonstrated, the tolerance is much smaller in patients with nonmalignant chronic pain than in those with oncologic pain, suggesting that the necessity of increasing the dose in patients with malignant disease is more likely due to the tumour growth than to a real toler ance. 3 l Recently, many clinical trials are being focused on diminishing the degree of toler ance using different drugs. Somatostatine, clonidine, encephalines and midazolam have been employed with promising re sults.32, 33 However, the use of new drugs via the spinal route needs further studies before being used in man.34
Is there a risk of respiratory depression?
Theoretically, using the epidural route, respiratory depression can occur within 2 hours after the administration of morphine, due to blood absorption. With the intra thecal route, this complication may appear between 6 and 12 hours after an injection, Chronic pain in SCI patients 727 probably by ascending the cerebrospinal fluid (CSF) pathways. 35 The incidence of patients who required naloxone ranged from 0. 25 to 0.40% in a study carried out in Sweden36 and from 1. 9 to 2.3% in another review in 74 American .
. . 3 7 . . � nStItutIOns. In patients With chronic pain it IS really a very rare complication, because the pain strongly stimulates the respiratory centre. 38 In our experience of over 100 patients treated with intrathecal morphine since 1986 (including malignant pain), only two cases of respiratory depression have been encoun tered.
Currently, we may observe an increase in the use of intrathecal morphine infusions for treating those patients with refractory, de afferentation pain. 39-41
Conclusion
Chronic pain in SCI patients may require a specialised approach since in some cases it is necessary to use aggressive therapies. It is very important to evaluate the type and location of the pain because some patients obtain sufficient relief using physical therapy and NSAIDs.
The spinal route of analgesia is sometimes the best one to provide pain relief. Toler ance is poor and dependence hardly exists. Therefore, we believe that an intrathecal continuous infusion of morphine is a valu able procedure in the management of chronic pain in SCI patients, when other treatm . ents have failed and a good response to the mtrathecal dose test is obtained.
To summarise:
1 It is important to investigate the type and location of the pain. 2 Most patients will experience a suffi cient degree of analgesia using the aforementioned drugs plus TENS (stage II). 3 We only recommend the trial of SCS in patients suffering from radicular pain. 4 In those patients with severe, refractory central pain, we have found that a continuous intrathecal infusion of morphine is very helpful.
